The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis.

DI, Swerdlow; MV, Holmes; KB, Kuchenbaecker; JE, Engmann; T, Shah; R, Sofat; R, Sofat; Y, Guo; C, Chung; A, Peasey; R, Pfister; SP, Mooijaart; HA, Ireland; M, Leusink; C, Langenberg; KW, Li; J, Palmen; P, Howard; JA, Cooper; F, Drenos; J, Hardy; MA, Nalls; YR, Li; G, Lowe; M, Stewart; SJ, Bielinski; J, Peto; NJ, Timpson; J, Gallacher; M, Dunlop; R, Houlston; I, Tomlinson; I, Tzoulaki; J, Luan; JM, Boer; NG, Forouhi; NC, Onland-Moret; der Schouw YT, van; RB, Schnabel; JA, Hubacek; R, Kubinova; M, Baceviciene; A, Tamosiunas; A, Pajak; R, Topor-Madry; S, Malyutina; D, Baldassarre; B, Sennblad; E, Tremoli; Faire U, de; L, Ferrucci; S, Bandenelli; T, Tanaka; JF, Meschia; A, Singleton; G, Navis; Leach I, Mateo; SJ, Bakker; RT, Gansevoort; I, Ford; SE, Epstein; MS, Burnett; JM, Devaney; JW, Jukema; RG, Westendorp; de Borst G, Jan; der Graaf Y, van; Jong PA, de; der Zee AH, Mailand-van; OH, Klungel; Boer A, de; PA, Doevendans; JW, Stephens; CB, Eaton; JG, Robinson; JE, Manson; FG, Fowkes; TM, Frayling; JF, Price; PH, Whincup; RW, Morris; DA, Lawlor; GD, Smith; Y, Ben-Shlomo; S, Redline; LA, Lange; M, Kumari; NJ, Wareham; WM, Verschuren; EJ, Benjamin; JC, Whittaker; A, Hamsten; F, Dudbridge; JA, Delaney; A, Wong; D, Kuh; R, Hardy; BA, Castillo; JJ, Connolly; der Harst P, van; EJ, Brunner; MG, Marmot; CL, Wassel; SE, Humphries; SE, Humphries; PJ, Talmud; M, Kivimaki; FW, Asselbergs; M, Voevoda; M, Bobak; H, Pikhart; JG, Wilson; H, Hakonarson; AP, Reiner; BJ, Keating; N, Sattar; AD, Hingorani; JP, Casas

doi:10.1016/s0140-6736(12)60110-x

Public

The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis.

Shared by NobleBlocks on Mar 14, 2012 • 12:00 AM UTC

Authors:

Swerdlow DI

Holmes MV

Kuchenbaecker KB

Abstract

<h4>Background</h4>A high circulating concentration of interleukin 6 is associated with increased risk of coronary heart disease. Blockade of the interleukin-6 receptor (IL6R) with a monoclonal antibody (tocilizumab) licensed for treatment of rheumatoid arthritis reduces systemic and articular infla...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!